Zoetis Inc. (ZTS) Could Launch First Long-Acting Anti-NGF Therapy for Cats in Q4 2025

We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. Zoetis Inc. is one of them.

Zoetis Inc. (NYSE:ZTS), a global leader in animal health, reported solid second-quarter 2025 results with revenue rising 4% year-over-year to $2.5 billion and net income up 15% to $718 million. Growth was driven by an 8% increase in companion animal product sales, led by flagship products such as Simparica Trio for parasite prevention and pain and dermatology treatments, including Rela Solens, Apoquel, and Cytopoint. On the back of these results, ZTS raised its full-year revenue forecast to $9.45–$9.6 billion and guided adjusted earnings per share to between $6.30 and $6.40.

In September, the company announced a major pipeline milestone with a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) for Portela® (relfovetmab). This monoclonal antibody is designed to treat osteoarthritis pain in cats, potentially offering up to three months of relief from a single injection. If approved by the European Commission in Q4 2025, it would become the first long-acting anti-NGF therapy for cats, addressing a widespread but underdiagnosed condition affecting an estimated 40% of the feline population.

Zoetis Inc. (NYSE:ZTS) will provide further updates on its financial and strategic outlook during its third-quarter earnings webcast and conference call scheduled for November 4, 2025, with CEO Kristin Peck and CFO Wetteny Joseph.

While we acknowledge the potential of ZTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.